BUZZ-Capricor surges as FDA resumes review of muscle‑wasting disease drug
Reuters03-10
BUZZ-Capricor surges as FDA resumes review of muscle‑wasting disease drug
** Shares of drug developer Capricor TherapeuticsCAPR.O rise 15.4% to $35.2
** CAPR says U.S. FDA has lifted its complete response letter and resumed review of deramiocel, CAPR's therapy for Duchenne muscular dystrophy
** Duchenne muscular dystrophy is a genetic disease that weakens muscles and affects the heart
** FDA said in its complete response letter last August the data submitted for deramiocel did not meet efficacy requirements and asked the company to provide additional evidence
** Co says the FDA has set a target action date of August 22, 2026, after reviewing late-stage data that the company disclosed last year
** Including session's move, CAPR stock was up 17.3% YTD
(Reporting by Sahil Pandey and Padmanabhan Ananthan in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments